• OPEN AN ACCOUNT
Indian Indices
Nifty
25,227.35 -58.00
(-0.23%)
Sensex
82,327.05 -173.77
( -0.21%)
Bank Nifty
56,625.00 15.25
( 0.03%)
Nifty IT
35,330.80 -278.25
( -0.78%)
Global Indices
Nasdaq
45,502.84 -876.59
(-1.89%)
Dow Jones
6,574.01 -182.10
(-2.70%)
Hang Seng
48,192.70 -387.74
(-0.80%)
Nikkei 225
9,427.47 -81.93
(-0.86%)
Forex
USD-INR
88.81 0.04
(0.05%)
EUR-INR
103.01 -0.16
(-0.15%)
GBP-INR
118.58 -0.38
(-0.32%)
JPY-INR
0.58 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

AstraZeneca Pharma gets CDSCO nod for Enhertu
Oct 06,2025
Through this approval, Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease.

The company’s standalone net profit surged 60.1% to Rs 56.08 crore on 35.8% increase in revenue from operations to Rs 526.31 crore in Q1 FY26 over Q1 FY25.

The scrip advanced 1.12% to settle at Rs 9324.70 on the BSE.